Stay updated on BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.

Latest updates to the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a Phase 2 clinical trial for BTX 1204 in patients with moderate atopic dermatitis, while a new version number has been added.SummaryDifference41%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check94 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the BTX 1204 Safety in Moderate Atopic Dermatitis Clinical Trial page.